TriangleCD371-specific/YSNVz/I-18 CAR T cells (NCT06017258)
CD371-specific/YSNVz/I-18 CAR T cells trial for Refractory Acute Myeloid Leukemia (NCT06017258). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
CAR T cells transformed lymphoid leukemias. In acute myeloid leukemia they have mostly failed: the cells tire, and the leukemia carries on.
The idea: a receptor built to resist exhaustion, on cells that also pump out their own alarm signal.
At Memorial Sloan Kettering, a patient's T cells get a receptor for CD371, a marker on AML cells, with an altered signaling domain to slow burnout, plus a gene to secrete interleukin-18, which rallies other immune cells.
In the first five patients, the cells expanded from one small infusion. Three, each refractory to five or more prior treatments, cleared their leukemia. Two at the higher dose had serious side effects, so the dose was reduced.
Mark Geyer leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.